The goal of this clinical trial is to learn which dose of study drug IBIO-600 has the right balance of safety, tolerability and impact on body composition in overweight and obese adult participants.
Aged 18 to 65 years of age
In good general health, with no significant medical history
BMI between ≥ 27.0 and ≤ 34.90 kg/m2
History of self-reported stable body weight (defined as change of no more or less than ± 5%) within 90 days of Screening.
An underlying physical or psychological medical conditions that, in the opinion of the PI or medical designee, would make the participant unlikely to comply with the protocol or complete the study per protocol.
History or active diagnosis of diabetes (Type 1 or 2).
History of insulinoma or recurrent hypoglycemia (≥ 3 episodes in past 3 months).
History or presence of clinically significant muscle disease